clinical trial · NCT06237426
An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD
Post Traumatic Stress DisorderMethylone
brief summary
This is an extension study of participants who previously completed a Transcend-sponsored clinical trial evaluating TSND-201 as a treatment for PTSD. Participants will be followed for up to 52 weeks. During the 52 week period, PTSD symptoms and safety will be assessed monthly. Participants' PTSD symptoms will be assessed at each observational visit and if criteria for Relapse has been met, participants may be eligible to receive a course of TSND-201 treatment.
started
Mar 6, 2024
primary completion
Oct 6, 2025
completion
Oct 6, 2025
last updated
Nov 25, 2025
official title
A 52-Week, Open-Label Evaluation of the Long-term Efficacy and Safety of Single and Repeated Treatments With Methylone for the Treatment of PTSD IMPACT-EXT (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol